Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy | Biogen
NS Innovation: la cumbre en neurociencias que cambiará la vida de millones de pacientes - Infobae
☑️Biogen México — Supplier from Mexico, experience with UNOPS — Health, Laboratory & Measurement, Research, Science & Innovation sectors — DevelopmentAid
Amanda Pereira Silva - Patient Services Analyst Pl - Biogen | LinkedIn
admin – Page 2 – PSP Society of Canada
Biogen MA Inc. 225 Binney Street Cambridge, MA 02142 United States PROTOCOL NUMBER: 251PP301 / NCT03068468 Biogen Idec Research
Biogen on Twitter: "We'll be showcasing our work in neuroscience including the areas of multiple sclerosis (#MS), spinal muscular atrophy (#SMA), Alzheimer's Disease (#AD) and progressive supranuclear palsy (#PSP) with poster and
Biogen pays $300M to Bristol-Myers for another potential Alzheimer's drug - Boston Business Journal
Medscape Neurology - After disappointing trial results, Biogen will discontinue development of gosuranemab for PSP and other primary tauopathies. http://ms.spr.ly/6182Tn3Cq | Facebook
Biogen | Contract Pharma
Biogen abandons tau antibody for Alzheimer's after phase 2 miss | pharmaphorum
PSPH (Human) Recombinant Protein (Q01) - BIOGEN Científica
Biogen on Twitter: "#DYK progressive supranuclear palsy (#PSP) wasn't discovered until 1963 due to its resemblance to Parkinson's disease? #PSPAwarenessMonth https://t.co/59rxSezyHe" / Twitter
Corio PSP™ – Detox RejuveNation
Biogen on Twitter: "Chris Henderson, VP, Neuromuscular and Movement Disorders Research Unit, highlights the importance of an early Progressive Supranuclear Palsy (PSP) diagnosis #PSPAwareness https://t.co/xDnZaZYYhT" / Twitter
Cure PSP - Can Progressive Supranuclear Palsy (PSP) be treated at all? The PASSPORT trial is investigating whether a new investigational study drug may slow the progression of PSP. Biogen plan to
Biogen chalks up another failure, but investors' eyes remain firmly on Alzheimer's | Fierce Biotech
What's in Biogen's Clinical Pipeline?
Biogen y Eisai aseguran que su fármaco lecanemab frena el deterioro cognitivo en el alzhéimer | Sociedad | EL PAÍS
Biogen on Twitter: "Progressive Supranuclear Palsy (#PSP) Awareness Month may be over, but the work doesn't end here. #PSPAwareness https://t.co/oC0MNF0IVD" / Twitter
Biogen on Twitter: "#DYK…Progressive supranuclear palsy (#PSP) is a neurodegenerative disorder that affects the brain cells controlling balance, walking, coordination, eye movement, speech, swallowing and thinking. #AANAM https://t.co/uYb551MjJi" / Twitter
PSP — Coleen Heaver
After Recent Tau Failure, Biogen Licenses Tau Therapeutic from Ionis for Alzheimer's Disease | BioSpace
Biogen Study - CurePSP
